奥马珠单抗治疗慢性自发性荨麻疹的应答与复发预测因素:470例患者研究
这项意大利多中心回顾性研究纳入470例慢性自发性荨麻疹患者,分析基线总IgE和D-二聚体及临床参数与奥马珠单抗应答及停药后复发的关系。基线总IgE在应答者中显著高于无应答者(P=0.0002),D-二聚体与应答无关;疾病病程与首次和第二次复发均显著相关(P<0.0001和P=0.0105),基线UAS7仅与首次复发相关(P=0.0023)。
要点
- 基线总IgE在奥马珠单抗应答者中显著高于无应答者(P=0.0002)。
- 基线D-二聚体与奥马珠单抗应答无相关性。
- 疾病病程在首次和第二次复发患者中均显著更长(P<0.0001和P=0.0105)。
核心结论
- 本研究证实基线总IgE是预测慢性自发性荨麻疹患者对奥马珠单抗应答的可靠生物标志物。
- 本研究不支持基线D-二聚体作为预测奥马珠单抗应答的标志物,与既往研究结果不同。
- 奥马珠单抗治疗前慢性自发性荨麻疹病程和基线UAS7可能是复发风险的临床标志物。
研究设计与样本
- 意大利多中心回顾性研究,纳入470例慢性自发性荨麻疹患者。
- 基线总IgE在340例患者中检测,基线D-二聚体在342例患者中检测。
- 疾病活动度采用荨麻疹活动度评分7(UAS7)在奥马珠单抗开始后第1周和第12周评估。
- 复发在首次和第二次治疗疗程后分别于2个月和3个月间隔内评估。
主要发现
- 基线总IgE在应答者中显著高于无应答者(P=0.0002)。
- 基线D-二聚体与奥马珠单抗应答无相关性。
- 基线总IgE和D-二聚体与首次或第二次复发均无相关性。
- 疾病病程在经历首次或第二次复发的患者中均显著更长(P<0.0001和P=0.0105)。
- 基线UAS7仅与首次复发相关(P=0.0023)。
关键数值与推荐
- 慢性自发性荨麻疹定义为自发出现风团和/或血管性水肿≥6周。
- 奥马珠单抗是一种抗IgE单克隆抗体,对难治性慢性自发性荨麻疹有效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic spontaneous urticaria (CSU) is defined as spontaneous occurrence of wheals and/or angioedema for ≥6 weeks. Omalizumab is a monoclonal anti-IgE antibody effective in refractory CSU, but its mechanism of action and markers predictive of response remain not completely defined. OBJECTIVES: To correlate baseline levels of two proposed biomarkers, total IgE (bIgE) and d-dimer (bd-dimer), and clinical parameters to omalizumab response and to relapses after drug withdrawal. METHODS: In this retrospective Italian multicentre study, clinical data were collected in 470 CSU patients, and bIgE and bd-dimer were measured in 340 and 342 patients, respectively. Disease activity was determined by Urticaria Activity Score 7 (UAS7) at week 1 and 12 after omalizumab starting. Relapses were evaluated during a 2- and 3-month interval after a first and a second course of treatment, respectively. RESULTS: bIgE correlated to a good response to omalizumab since levels were significantly higher in responders than non-responders (P = 0.0002). Conversely, bd-dimer did not correlate to response. There was no correlation between both bIgE and d-dimer and either first or second relapse. Disease duration was significantly longer in patients who experienced either first or second relapse (P < 0.0001 and P = 0.0105, respectively), while baseline UAS7 correlated only to first relapse (P = 0.0023). CONCLUSIONS: Our study confirms bIgE as a reliable biomarker predicting response to omalizumab in CSU, while it does not support the usefulness of bd-dimer unlike previous findings. CSU duration before omalizumab and baseline UAS7 may be clinical markers of relapse risk.
引用
- Marzano AV, Genovese G, Casazza G, et al. Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients. J Eur Acad Dermatol Venereol. 2018. PMID: 30451325. doi:10.1111/jdv.15350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。